Flagship Harbor Advisors LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 5.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 4,067 shares of the company’s stock after selling 219 shares during the period. Flagship Harbor Advisors LLC’s holdings in Eli Lilly and were worth $1,319,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Cordant Inc. bought a new stake in shares of Eli Lilly and during the first quarter worth approximately $25,000. HWG Holdings LP acquired a new stake in shares of Eli Lilly and in the fourth quarter valued at approximately $28,000. Icapital Wealth LLC acquired a new stake in shares of Eli Lilly and in the first quarter valued at approximately $28,000. Selective Wealth Management Inc. acquired a new stake in shares of Eli Lilly and in the first quarter valued at approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Eli Lilly and in the first quarter valued at approximately $33,000. Institutional investors own 82.45% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the subject of several research analyst reports. Morgan Stanley boosted their price objective on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. UBS Group upgraded shares of Eli Lilly and to a “buy” rating in a report on Thursday. Citigroup upped their price target on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. StockNews.com upgraded shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $330.44.
Eli Lilly and Price Performance
Shares of NYSE:LLY opened at $296.48 on Thursday. The stock has a market cap of $281.71 billion, a PE ratio of 47.29, a PEG ratio of 1.95 and a beta of 0.38. The company’s fifty day moving average is $314.65 and its 200 day moving average is $304.11. Eli Lilly and Company has a 52 week low of $220.20 and a 52 week high of $335.33. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70.
Eli Lilly and (NYSE:LLY – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The firm had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. During the same period last year, the business earned $1.87 EPS. Eli Lilly and’s revenue was down 3.7% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 7.97 earnings per share for the current year.
Eli Lilly and Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a $0.98 dividend. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.32%. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.
About Eli Lilly and
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.